
==== Front
BMC Infect Dis
BMC Infect Dis
BMC Infectious Diseases
1471-2334
BioMed Central London

9792
10.1186/s12879-024-09792-1
Research
Comparison of performances between risk scores for predicting mortality at 30 days in patients with community acquired pneumonia
Tuta-Quintero Eduardo 1
https://orcid.org/0000-0002-8873-9779
Goyes Alirio Rodrigo Bastidas alirio.bastidas@unisabana.edu.co

1
Guerrón-Gómez Gabriela 12
Martínez María C. 1
Torres Daniela 1
Schloss Carolina 1
Camacho Julian 1
Bonilla Gabriela 1
Cepeda Daniela 1
Romero Paula 1
Fuentes Yuli 1
Garcia Esteban 2
Acosta David 1
Rodríguez Santiago 1
Alvarez David 1
Reyes Luis F. 345
1 https://ror.org/02sqgkj21 grid.412166.6 0000 0001 2111 4451 School of Medicine, Universidad de La Sabana. Km 7, Autonorte de Bogota, Chía, Cundinamarca 250001 Colombia
2 https://ror.org/02sqgkj21 grid.412166.6 0000 0001 2111 4451 Master’s Student in Epidemiology, Universidad de La Sabana, Chía, Colombia
3 https://ror.org/02sqgkj21 grid.412166.6 0000 0001 2111 4451 Unisabana Center for Translational Science, Universidad de La Sabana, Chía, Colombia
4 grid.412166.6 0000 0001 2111 4451 Clinica Universidad de La Sabana, Chía, Colombia
5 https://ror.org/052gg0110 grid.4991.5 0000 0004 1936 8948 Pandemic Sciences Institute, University of Oxford, Oxford, UK
3 9 2024
3 9 2024
2024
24 9124 2 2024
21 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

Risk scores facilitate the assessment of mortality risk in patients with community-acquired pneumonia (CAP). Despite their utilities, there is a scarcity of evidence comparing the various RS simultaneously. This study aims to evaluate and compare multiple risk scores reported in the literature for predicting 30-day mortality in adult patients with CAP.

Methods

A retrospective cohort study on patients diagnosed with CAP was conducted across two hospitals in Colombia. The areas under receiver operating characteristic curves (ROC-curves) were calculated for the outcome of survival or death at 30 days using the scores obtained for each of the analyzed questionnaires.

Results

A total of 7454 potentially eligible patients were included, with 4350 in the final analysis, of whom 15.2% (662/4350) died within 30 days. The average age was 65.4 years (SD: 21.31), and 59.5% (2563/4350) were male. Chronic kidney disease was 3.7% (9.2% vs. 5.5%; p < 0.001) (OR: 1.85) higher in subjects who died compared to those who survived. Among the patients who died, 33.2% (220/662) presented septic shock compared to 7.3% (271/3688) of the patients who survived (p < 0.001). The best performances at 30 days were shown by the following scores: PSI, SMART-COP and CURB 65 scores with the areas under ROC-curves of 0.83 (95% CI: 0.8–0.85), 0.75 (95% CI: 0.66–0.83), and 0.73 (95% CI: 0.71–0.76), respectively. The RS with the lowest performance was SIRS with the area under ROC-curve of 0.53 (95% CI: 0.51–0.56).

Conclusion

The PSI, SMART-COP and CURB 65, demonstrated the best diagnostic performances for predicting 30-day mortality in patients diagnosed with CAP. The burden of comorbidities and complications associated with CAP was higher in patients who died.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12879-024-09792-1.

Keywords

Pneumonia
Risk score
Mortality
Observational study
http://dx.doi.org/10.13039/501100010628 Universidad de La Sabana MED-326-2022 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Community-acquired pneumonia (CAP) is the leading infectious cause of death worldwide, with a global incidence ranging from 1 to 14 cases per 1,000 individuals annually, resulting in approximately 2.5 million deaths each year [1, 2]. Hospitalization is required for 22–42% of patients, with 10–14% admitted to the Intensive Care Unit (ICU). Mortality rates range from 10 to 12% in hospitalized patients and can reach up to 35% for those requiring ICU care within 30 days [1, 3]. Early recognition of patients at high risk for complications and mortality, using clinical judgment and various risk scoring systems, is recommended by numerous scientific associations and experts [3, 4]. The initial clinical assessment of CAP is crucial for determining the extent of disease involvement, establishing the appropriate site for in-hospital treatment, and estimating the short- and long-term mortality risk [5–7].

The risk scores (RS) most used to predict 30-day mortality in CAP are the Pulmonary Severity Index (PSI) and the CURB-65 (confusion, blood urea nitrogen > 7 mmol/L, respiratory rate ≥ 30/min, systolic blood pression < 90 mmHg or Diastolic Blood Pression ≤ 60 mmHg, age ≥ 65 years) [7–9]. Kaal et al. [10] described that the use of the CURB-65 as a severity assessment tool in patients with CAP in the emergency department was associated with a lower risk of 30-day mortality compared to the PSI (OR: 0.89; 95% CI: 0.83–0.96, p = 0.003). Mortality risk in CAP patients has been validated and compared with various other scores [11]. For instance, the Pneumonia Shock Score demonstrated the area under receiver operating characteristic curve (ROC-curve) for 30-day mortality of 0.739 (95% CI: 0.709–0.769, p < 0.001) [12]. Similarly, the ADROP score achieved the area under ROC-curve of 0.846 (95% CI: 0.790–0.903) [11, 12]. However, none of these scores exhibited excellent performances.

Numerous studies have compared the diagnostic performances of up to four or five questionnaires in predicting 30-day mortality in patients with CAP. However, more than ten different scales are currently available for this purpose. This gap in evidence has led to inconsistencies between clinical practice guidelines and expert consensus regarding the best tool for estimating short-term mortality risk [3, 13, 14]. Therefore, the aim of this study was to compare 16 different severity questionnaires, including various clinical variables and radiological findings, to predict 30-day mortality in adult patients with CAP.

Methods

Study design

A retrospective cohort study on patients diagnosed with CAP was conducted across two hospitals in Colombia. Patients were assessed and admitted to emergency room and ICU from January 2010 to December 2019.

Inclusion criteria

Subjects aged 18 years or older, regardless of gender, who had received a diagnosis of CAP in accordance with the guidelines of the American Thoracic Society and the Infectious Diseases Society of America (ATS/IDSA) [2, 14, 15], were included in the study. Patients were required to present the following: respiratory symptoms (including cough, purulent sputum, and dyspnea), systemic involvement (fever and altered consciousness), radiographic findings suggestive of pneumonia, observed in either chest X-rays or chest computed tomography scan (alveolar and/or interstitial opacities, the presence of pulmonary consolidations, and unilateral or bilateral pleural effusion).

Furthermore, the medical records were required to contain sufficient information to calculate the following scores: CURB-65, CRB-65, SCAP, SOAR, CORB, ADROP, NEWS, Pneumonia Shock, REA-ICU, PSI, SMART-COP, SMRT-CO, SRIS, qSOFA, CAPSI and Charlson Comorbidity Index. The variables for each questionnaire are described in Supplementary File 1. Patients with incomplete medical records, those who developed nosocomial pneumonia, individuals with decompensated heart failure, pulmonary fibrosis, and pulmonary embolism were excluded from this study.

Variables

The study included the following variables: sociodemographic variables (age and sex), vital signs, level of consciousness, comorbidities, radiographic finding, arterial blood gas analysis, pulse oximetry, white blood cell count, blood glucose level, blood urea nitrogen, serum albumin, serum sodium, need for ICU admission, invasive mechanical ventilation (IMV) and/or vasopressor support. The dependent variable was survival at 30 days following the diagnosis of CAP. To minimize potential errors in classifying the studied outcomes, the research team obtaining information from clinical records had medical experience for diagnosing CAP. To reduce the risk of data entry errors, at least two team members reviewed the information during the transcription process into the database.

Sample size

To calculate the sample size, data from the study by Lim et al. [16] which reported a sensitivity of 75% and specificity of 69% for CURB-65, and data from España et al. [17] which reported a sensitivity of 92.1% and specificity of 73.8% for SCAP, were used. Using the formula for sample size for paired diagnostic tests, with an expected mortality rate of 14%, a power of 90%, and a statistical significance level of 0.05, a minimum of 2168 subjects were required.

Statistical analysis

The data was obtained directly from medical records and subsequently transcribed into the Research Electronic Data Capture (REDCap) software [18, 19]. Then it was analyzed using licensed SPSS 25 software (IBM Corp. IBM SPSS Statistics for Windows. Version 25.0). Qualitative variables were reported in percentages and frequencies, while quantitative variables were summarized as mean and standard deviation (SD) for those with a normal distribution and median and interquartile range for those with a non-normal distribution. Bivariate analysis was conducted using the chi-square test for qualitative variables and the T-student test or Mann-Whitney U test for quantitative variables, depending on their distribution. Sensitivity, specificity, the areas under ROC-curves, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (LR+), and negative likelihood ratio (LR-) were calculated for the outcome of survival or death at 30 days using the scores obtained from all the analyzed questionnaires.

The established cutoff point for each questionnaire, as detailed in Supplementary Table 2, was used. The calculated the areas under ROC-curves were compared using the DeLong test. The interpretation of the areas under ROC-curves were as follows: 0.50 indicated an absence of discriminatory capacity; 0.51 to 0.60 indicated nearly no discriminatory capacity; 0.61 to 0.69 indicated poor discriminatory capacity; >0.7 to 0.8 indicated acceptable discriminatory capacity; >0.80 to 0.90 indicated excellent discriminatory capacity, and > 0.90 indicated outstanding discriminatory capacity [20, 21]. Statistical significance was considered when the p-value was < 0.05.

Missing data

An imputation analysis addressed missing data, employing weighted mean imputation for quantitative variables and logistic regression for qualitative variables with a loss of less than 10% [20]. Variables with more than 10% data loss were excluded. A comparison between non-imputed and imputed results ensured that imputation did not introduce bias or significantly alter the original data.

Results

In total, there were 7454 potentially eligible patients, and 4350 entered the final analysis, of which 15.2% (662/4350) died within 30 days Fig. 1. The average age was 65.4 years (SD: 21.31), and 59.5% (2563/4350) were male Table 1. Altered consciousness was present in 33.1% of patients who died compared to 10.1% (371/3688) of patients who survived. The prevalence of systemic hypertension and chronic obstructive pulmonary disease was 12.4% (46.1% vs. 58.5%; p < 0.001) and 3.7% (18.1% vs. 21.8%; p < 0.001) lower in the group of living patients compared to those who died. respectively. Chronic kidney disease was 3.7% (9.2% vs. 5.5%; p < 0.001) higher in subjects who died compared to those who survived.

Fig. 1 Patient admission flowchart

Table 1 General characteristics of the population

	Total n = 4350	Alive n = 3688	Death n = 662	P value	
Age years, m(SD)	65.4 (21.31)	63.5 (21.39)	76.3 (17.23)	< 0.001	
Male, n(%)	2563 (59.5)	2188 (58.9)	375 (63.8)	0.197	
Days of symptoms, m(SD)	4.9 (3.83)	5.1 (3.87)	4.3 (3.5)	< 0.001	
Headache, n(%)	329 (7.6)	311 (8.4)	18 (2.7)	< 0.001	
Altered consciousness, n(%)	590 (13.6)	371 (10.1)	219 (33.1)	< 0.001	
Oxygen saturation %, m(SD)	88.7 (7.45)	89.1 (6.7)	86.1 (10.28)	< 0.001	
Initial FiO2%, m(SD)	29.8 (13.79)	28.5 (12.34)	36.1 (17.99)	< 0.001	
Systemic hypertension, n(%)	2086 (48)	1699 (46.1)	387 (58.5)	< 0.001	
Chronic heart failure, n(%)	605 (13.9)	447 (12.1)	158 (23.9)	< 0.001	
Acute myocardial infarction, n(%)	220 (5.1)	168 (4.6)	52 (7.9)	< 0.001	
Cerebrovascular disease, n(%)	366 (8.4)	258 (7)	108 (16.3)	< 0.001	
COPD, n(%)	1158 (26.6)	941 (25.5)	217 (32.8)	< 0.001	
Diabetes Mellitus, n(%)	134 (3.1)	104 (2.8)	30 (4.5)	0.019	
Immunosuppression, n(%)	191 (4.4)	148 (4)	43 (6.5)	0.004	
Chronic kidney disease, n(%)	262 (6)	201 (5.5)	61 (9.2)	< 0.001	
Notes SD: Standard deviation; n: number; FiO2: Fraction of inspired oxygen; COPD: Chronic obstructive pulmonary disease

Laboratory tests

The oxygen arterial pressure/fraction of inspired oxygen in the patients who survived was 233 (SD: 69.7), compared to 203.8 (SD: 88.5) in the patients who died (p < 0.001) Table 2. The pH was 7.38 in the deceased patient’s group versus 7.42 in the surviving group (OR: 4.02 CI: 95%. p < 0.001). Likewise, lactate was 1 unit higher (3 vs. 2; p < 0.001) in the deceased subjects compared to the survivors. Creatinine and blood urea nitrogen were 0.2 (1.3 vs. 1.5; p = 0.041) and 13.2 (23.3 vs. 36.5; OR: 3.92 CI: 95%; p < 0.001) lower in the subjects who survived compared to the deceased group.

Table 2 Laboratory tests

	Total population n = 4350	Alive n = 3688	Death n = 662	P value	
pH, m(SD)	7.41 (0.07)	7.42 (0.06)	7.38 (0.1)	< 0.001	
PO2, m(SD)	62.5 (19.87)	62.1 (19.32)	64.2 (22.26)	0.023	
PCO2, m(SD)	33.2 (8.85)	33 (8.32)	34.4 (10.96)	0.001	
HCO3, m(SD)	20.9 (4.31)	21 (4.02)	20.3 (5.47)	0.002	
BE, m(SD)	-2.8 (4.31)	-2.5 (3.92)	-4.0 (5.7)	< 0.001	
Lactate, m(SD)	2.2 (1.75)	2.1 (1.32)	3.0 (2.76)	< 0.001	
PaO2/FiO2, m(SD)	228 (74.19)	233 (69.7)	203.8 (88.95)	< 0.001	
White cells count cell x 103, m(SD)	12.1 (6463.95)	12.4 (6204.46)	12 (7748.81)	0.543	
Hemoglobin g/dL, m(SD)	13.4 (2.39)	13.5 (2.27)	12.4 (2.83)	< 0.001	
Hematocrit %, m(SD)	40 (7.11)	40.4 (6.78)	37.7 (8.35)	< 0.001	
Platelets microliters, m(SD)	256.9 (104.1)	259.6 (102.24)	242.1 (112.78)	< 0.001	
Sodium meq/L, m(SD)	137.5 (6.86)	137.2 (5.86)	138.7 (9.86)	< 0.001	
Glucose mg/dL, m(SD)	135.3 (69.31)	134.1 (67.66)	140.7 (75.97)	0.036	
Albumin mg/dL, m(SD)	2.9 (1.17)	3 (1.29)	2.8 (0.47)	< 0.001	
Creatinine mg/dL, m(SD)	1.4 (2.97)	1.3 (3.2)	1.5 (1.3)	0.041	
BUN mg/dL, m(SD)	25.5 (18.92)	23.3 (16.83)	36.5 (24.42)	< 0.001	
Notes SD: Standard deviation; PO2: Partial pressure of oxygen; PCO2: Partial Pressure of Carbon Dioxide; HCO3: Bicarbonate; BE: Base excess; PaO2/FiO2: The ratio of partial pressure of oxygen in arterial blood to the fraction of inspiratory oxygen concentration; BUN: Blood urea nitrogen

In-hospital treatment and complications

Among the patients who died, 33.2% (220/662) presented septic shock compared to 7.3% (271/3688) of the patients who survived (p < 0.001) Table 3. The use of systemic corticosteroids and vasopressor support was 32.8% (217/662) and 33.2% (159/662), respectively, in the mortality group. The ICU requirement was 25.4% (168/662) in deceased patients versus 11.2% (414/3688) in living patients (p < 0.001). Of the patients who deceased, 24% (159/662) required invasive mechanical ventilation, whereas 7.2% (266/3688) of the subjects who survived needed (p < 0.001).

Table 3 Medical treatment and complications

	Total population
n = 4350	Alive
n = 3688	Death
n = 662	P value	
Septic Shock, n(%)	491 (11.3)	271 (7.3)	220 (33.2)	< 0.001	
Vasopressor support, n(%)	419 (11.3)	260 (7.3)	159 (33.2)	< 0.001	
Corticosteroid use, n(%)	984 (22.6)	767 (20.8)	217 (32.8)	< 0.001	
Hydrocortisone, n(%)	351 (35.7)	252 (32.9)	99 (45.6)	< 0.001	
Methylprednisolone, n(%)	299 (30.4)	233 (30.4)	66 (30.6)	0.969	
Prednisone, n(%)	297 (30.2)	257 (33.5)	40 (18.5)	< 0.001	
ICU admission, n(%)	582 (13.4)	414 (11.2)	168 (25.4)	< 0.001	
Length of stay in ICU, m(SD)	10.6 (17.6)	11.6 (20.25)	8 (6.41)	< 0.001	
Mechanical ventilation, n(%)	425 (9.8)	266 (7.2)	159 (24)	< 0.001	
Notes n: number; SD: Standard deviation; ICU; Intensive care unit

Performances of RS for 30-day mortality prediction

The best performances at 30 days were observed in the PSI, SMART-COP, and CURB 65 scores with the areas under ROC-curves of 0.83 (95% CI: 0.8–0.85), 0.75 (95% CI: 0.66–0.83), and 0.73 (95% CI: 0.71–0.76), respectively, Table 4. Scores with lower performances were SIRS and SOAR with the areas under ROC-curves of 0.53 (95% CI: 0.51–0.56) and 0.65 (95% CI: 0.62–0.68), respectively. The DeLong’s test was significant with a result minor than 0.05.

Table 4 Performances of risk scores in community acquired pneumonia for 30-Day mortality prediction

	SE
(CI 95%)	SP (CI 95%)	PPV (CI 95%)	NPV (CI 95%)	LR+ (CI 95%)	LR- (CI 95%)	The areas under ROC-curves (CI 95%)	P value*	
CURB-65 ≥ 2	81.3 (79.9–82.7)	51.4 (49.6–53.2)	25.1 (23.6–26.7)	93.2 (92.3–94.1)	1.67 (1.527–1.836)	0.36 (0.331–0.398)	0.73 (0.71–0.76)	< 0.001	
CRB-65 ≥ 2	55.2 (53.7–56.8)	78.5 (77.2–79.8)	32.1 (30.7–33.6)	90.5 (89.6–91.4)	2.57 (2.196–2.999)	0.57 (0.488–0.666)	0.72 (0.69–0.74)	< 0.001	
SCAP ≥ 20	42.4 (40.3–44.5)	86.9 (40-133.7)	41.4 (39.3–43.5)	94 (93-126.9)	1.21 (0.371–3.929)	0.29 (0.089–0.947)	0.73 (0.7–0.76)	< 0.001	
CORB ≥ 2	43.2 (41.6–44.8)	80.3 (79-81.6)	28.9 (27.4–30.3)	88.4 (87.4–89.4)	2.19 (1.85–2.596)	0.71 (0.597–0.838)	0.66 (0.63–0.68)	< 0.001	
ADROP ≥ 3	58.6 (58.6–58.6)	74.3 (72.7–75.9)	31.8 (30.1–33.4)	89.8 (88.7–90.9)	2.28 (1.96–2.654)	0.56 (0.479–0.649)	0.71 (0.69–0.73)	< 0.001	
NEWS ≥ 7	62.4 (60.7–64.1)	64.2 (62.5–65.9)	24.1 (22.5–25.6)	90.4 (89.3–91.4)	1.74 (1.536–1.976)	0.59 (0.517–0.665)	0.69 (0.66–0.72)	< 0.001	
PNEUMONIA SHOCK ≥ 3	74.7 (32.2-117.3)	57.7 (55.7–59.6)	30.3 (28.5–32.1)	90.3 (89.1–91.5)	1.77 (1.586–1.967)	0.44 (0.393–0.488)	0.72 (0.69–0.74)	< 0.001	
REA ICU ≥ 7	37.2 (35.8-0)	87.2 (86.2–88.2)	25.9 (24.6–27.2)	92 (91.2–92.9)	2.9 (2.27–3.715)	0.72 (0.563–0.921)	0.71 (0.68–0.73)	< 0.001	
PSI ≥ 91	86.2 (85.2–134)	57.9 (56.4–59.5)	13 (12-14.1)	98.3 (97.9–98.7)	2.05 (1.781–2.36)	0.24 (0.206–0.273)	0.83 (0.8–0.85)	< 0.001	
SMART-COP ≥ 3	66.6 (65.2–68)	51.7 (50.2–53.2)	19.8 (18.7–21)	89.6 (88.7–90.5)	1.38 (1.27–1.497)	0.65 (0.595–0.701)	0.75 (0.66–0.83)	< 0.001	
SMRT-CO ≥ 3	62.6 (61.1–64.2)	64.8 (63.3–66.3)	25 (23.7–26.4)	90.2 (89.3–91.2)	1.78 (1.593–1.988)	0.58 (0.516–0.644)	0.67 (0.64–0.69)	< 0.001	
SOAR ≥ 2	69.4 (67.5–71.2)	53.1 (51-55.1)	23.7 (21.9–25.4)	89.2 (87.9–90.5)	1.48 (1.327–1.645)	0.58 (0.519–0.643)	0.65 (0.62–0.68)	< 0.001	
qSOFA ≥ 2	32.2 (30.8–33.6)	89.5 (88.5–90.4)	35.4 (34-36.8)	88 (87.1–89)	3.05 (2.432–3.827)	0.76 (0.604–0.951)	0.66 (0.64–0.69)	< 0.001	
SRIS	61 (59.6–62.5)	44 (42.5–45.5)	16.4 (15.3–17.5)	86.3 (85.3–87.3)	1.09 (1.014–1.172)	0.89 (0.824–0.952)	0.53 (0.51–0.56)	0.001	
CAPSI ≥ 4	68.4 (66.7–70)	62.7 (60.9–64.4)	26.6 (25.1–28.2)	90.9 (89.9–91.9)	1.83 (1.631–2.056)	0.5 (0.449–0.567)	0.71 (0.69–0.74)	< 0.001	
CHARLSON ≥ 3	86.4 (85.4–87.4)	40.3 (38.9–41.8)	20.6 (19.4–21.8)	94.3 (93.6–95)	1.45 (1.359–1.544)	0.34 (0.316–0.359)	0.71 (0.69–0.74)	< 0.001	
Notes SE: sensitivity; SP: specificity; PPV: positive predictive value; NPV: negative predictive value; LR: like hood ratio; The areas under ROC-curves: the area under operating characteristic curves

*DeLong test

Discussion

The analysis revealed that PSI, SMART-COP, and CURB 65 emerged as the top-performing predictors, while SIRS and SOAR demonstrated comparatively lower efficacy. PSI exhibited excellent performance in forecasting 30-day mortality, and SMART-COP and CURB 65 demonstrated acceptable accuracy. Noteworthy factors associated with fatal outcomes included advanced age, the presence of comorbidities (specifically cardiovascular, respiratory, and tobacco smoking-related), altered consciousness, acidosis, kidney dysfunction, reliance on vasopressor support, and admission to the ICU.

The PSI risk score has demonstrated greater discriminatory capacity due to variables such as age and comorbidities, which have a significant correlation with increased mortality in individuals over 75 years old with chronic kidney disease, lung neoplasms, and cerebrovascular disease [7, 22–25]. Zaki et al. [22] mention that the PSI identifies patients who can be treated on an outpatient basis, but it may overestimate severity, especially in young patients with severe respiratory failure and no comorbidities. Our data show that the PSI has greater discriminatory capacity for predicting short-term mortality due to the variables that structure it, which may support the published medical evidence.

Marti et al. [23] performed a meta-analysis to determine the performances of RS in pneumonia prognosis. They concluded new severity scores such as SMART-COP had better discriminative performance in predicting intensive respiratory or vasopressor support, as previously mentioned fatal outcomes, compared to PSI and CURB-65. Also, Saldías et al. [24] determined the performances of RS in predicting 30-day mortality with an area under ROC-curve of 0.77 (95% CI: 0.74–0.81) for SMART-COP. Consistent with our data, the performance of SMART-COP was also acceptable for predicting mortality compared to questionnaires such as PSI, CURB-65, SCAP, among others.

Despite its recognized role as a predictor of mortality [26–29], none of the examined RS in our study incorporated mechanical ventilation as a variable. Our findings underscored that the need for mechanical ventilation emerged as a significant risk factor for mortality, mirroring the observations made in a cohort of 3719 patients studied by Cilloniz et al. [30]. Mermiri et al. [31] highlighted the association of vasopressor use with increased 30-day mortality (RR: 2.97; 95% CI: 1.72–5.14; p < 0.001) and a heightened risk of acute kidney injury (RR: 3.17: 95% CI: 2.21–4.54; p < 0.001). In our investigation, only one RS identified vasopressor use as a factor linked to elevated mortality. It is noteworthy that a majority of existing RS omit vasopressor support and mechanical ventilation as variables impacting mortality, potentially limiting the predictive accuracy of severity assessments. Hence, the incorporation of these two variables into prevailing questionnaires could enhance their efficacy in predicting 30-day mortality in patients with CAP.

In the context of pneumonia, the interplay with pH is intricately tied to shifts in the body’s acid-base equilibrium. The severity of pneumonia, notably in complex cases featuring respiratory failure, can precipitate respiratory acidosis. Hypoxemia, acidosis, and cognitive disorientation serve as indicators of tissue hypoperfusion and correlate with elevated mortality rates in CAP patients [32]. Acidosis in CAP patients aligns with altered consciousness [25], identified as a risk factor for 30-day mortality in those with comorbidities [33], particularly within the initial 5 days of hospitalization [32, 33]. Addressing these acid-base imbalances holds pivotal importance in pneumonia management, especially in severe cases impacting respiratory function. Notably, risk assessment tools with enhanced discriminatory capabilities, such as SMART-COP and PSI, incorporate acidosis (pH less than 7.35) as a variable in their evaluation.

Altered consciousness is correlated with acidosis, azotemia, acute kidney injury, and chronic kidney disease [7, 26], all of which increase fatal outcomes in patients with CAP [34]. In a cohort of 1474 patients with CAP, Fernández et al. [35] demonstrated that in patients over 80 years old, 49% of those who died had altered consciousness (OR: 4.92 CI: 95%; p < 0.001). Zhang et al. showed that in the population over 85 years old who had altered consciousness, mortality increased 3.3 to 6.1 times, respectively [28]. Chronic kidney disease has been described as an independent factor for early mortality in CAP. One possible explanation for this finding is the immunosuppressive state that advanced chronic kidney disease can generate. In this scenario, there is immune deficiency caused by a decrease in dendritic cells and T and B lymphocytes, as well as a proinflammatory state [36, 37].

Limitations

Among the limitations of our study is its observational nature, with information obtained from clinical records, which may have omissions. Furthermore, we did not include a characterization of the microbiological etiology of CAP, or the treatments received by the patients. However, measures were implemented to minimize information bias, such as continuous training of personnel responsible for data collection and constructing the manuscript according to the STROBE checklist Supplementary Table 4. We believe that the achieved sample size supports the conclusions drawn. Additionally, the similarity of our population characteristics to those in other series and the use of ATS/IDSA [2, 14, 15] criteria help reduce the variability or differences with the cohorts described in other observational studies.

Conclusion

The PSI, SMART-COP and CURB 65 demonstrated the best diagnostic performances in predicting 30-day mortality in patients diagnosed with CAP. Older age, the presence of comorbidities, altered consciousness, acidosis, renal dysfunction, vasopressor support, and admission to the ICU were more prevalent in the group of deceased patients.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Acknowledgements

The authors are most thankful for the Universidad de La Sabana.

Author contributions

ETQ, ARB, GGG, MCM, DT, CS, JC, GB, DC, PR, YF, EG, DA, SR, DA, and LFRcontributed substantially to the study design, data analysis and interpretation, and manuscript writing. ETQ, ABG, GGG and DT had full access to all study data and takes responsibility for data integrity as well as for accuracy of the included data analysis and, especially, any adverse effects. All authors read and approved the final manuscript.

Funding

This work was supported by Universidad de la Sabana Grant MED-326-2022.

Data availability

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

The study was conducted in accordance with the principles of the current Helsinki Declaration, as well as local, regional, and international regulations pertaining to clinical research, including Colombian Law on Biomedical Research. Ethical approval was obtained from the Medical Ethics Committee of the Clínica Universidad de La Sabana (approval number 20220102). The confidentiality of their data was strictly maintained throughout the study.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Gadsby NJ Musher DM The Microbial etiology of community-acquired pneumonia in adults: from classical bacteriology to Host Transcriptional Signatures Clin Microbiol Rev 2022 35 4 e0001522 10.1128/cmr.00015-22 36165783
Gadsby NJ, Musher DM. The Microbial etiology of community-acquired pneumonia in adults: from classical bacteriology to Host Transcriptional Signatures. Clin Microbiol Rev. 2022;35(4):e0001522.36165783 10.1128/cmr.00015-22
2. Metlay JP Waterer GW Long AC Anzueto A Brozek J Crothers K Diagnosis and treatment of adults with community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America Am J Respir Crit Care Med 2019 200 7 e45 67 10.1164/rccm.201908-1581ST 31573350
Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45–67.31573350 10.1164/rccm.201908-1581ST
3. Nair GB Niederman MS Updates on community acquired pneumonia management in the ICU Pharmacol Ther 2021 217 107663 10.1016/j.pharmthera.2020.107663 32805298
Nair GB, Niederman MS. Updates on community acquired pneumonia management in the ICU. Pharmacol Ther. 2021;217:107663.32805298 10.1016/j.pharmthera.2020.107663
4. File TM Jr Ramirez JA Community-Acquired Pneumonia N Engl J Med 2023 389 7 632 41 10.1056/NEJMcp2303286 37585629
File TM Jr, Ramirez JA. Community-Acquired Pneumonia. N Engl J Med. 2023;389(7):632–41.37585629 10.1056/NEJMcp2303286
5. Khari S Salimi Akin Abadi A Pazokian M Yousefifard M CURB-65, qSOFA, and SIRS Criteria in Predicting In-Hospital mortality of critically ill COVID-19 patients; a Prognostic Accuracy Study Arch Acad Emerg Med 2022 10 1 e36 35765619
Khari S, Salimi Akin Abadi A, Pazokian M, Yousefifard M. CURB-65, qSOFA, and SIRS Criteria in Predicting In-Hospital mortality of critically ill COVID-19 patients; a Prognostic Accuracy Study. Arch Acad Emerg Med. 2022;10(1):e36.35765619
6. Pletz MW Blasi F Chalmers JD Dela Cruz CS Feldman C Luna CM International Perspective on the New 2019 American Thoracic Society/Infectious Diseases Society of America Community-Acquired Pneumonia Guideline: a critical Appraisal by A Global Expert Panel Chest 2020 158 5 1912 8 10.1016/j.chest.2020.07.089 32858009
Pletz MW, Blasi F, Chalmers JD, Dela Cruz CS, Feldman C, Luna CM, et al. International Perspective on the New 2019 American Thoracic Society/Infectious Diseases Society of America Community-Acquired Pneumonia Guideline: a critical Appraisal by A Global Expert Panel. Chest. 2020;158(5):1912–8.32858009 10.1016/j.chest.2020.07.089
7. Bradley J Sbaih N Chandler TR Furmanek S Ramirez JA Cavallazzi R Pneumonia Severity Index and CURB-65 score are good predictors of mortality in hospitalized patients with SARS-CoV-2 Community-Acquired Pneumonia Chest 2022 161 4 927 36 10.1016/j.chest.2021.10.031 34740594
Bradley J, Sbaih N, Chandler TR, Furmanek S, Ramirez JA, Cavallazzi R. Pneumonia Severity Index and CURB-65 score are good predictors of mortality in hospitalized patients with SARS-CoV-2 Community-Acquired Pneumonia. Chest. 2022;161(4):927–36.34740594 10.1016/j.chest.2021.10.031
8. Barlas RS Clark AB Loke YK Kwok CS Angus DC Uranga A Comparison of the prognostic performance of the CURB-65 and a modified version of the pneumonia severity index designed to identify high-risk patients using the International Community-Acquired Pneumonia collaboration cohort Respir Med 2022 200 106884 10.1016/j.rmed.2022.106884 35767924
Barlas RS, Clark AB, Loke YK, Kwok CS, Angus DC, Uranga A, et al. Comparison of the prognostic performance of the CURB-65 and a modified version of the pneumonia severity index designed to identify high-risk patients using the International Community-Acquired Pneumonia collaboration cohort. Respir Med. 2022;200:106884.35767924 10.1016/j.rmed.2022.106884
9. Chalmers JD Singanayagam A Akram AR Mandal P Short PM Choudhury G Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis Thorax 2010 65 10 878 83 10.1136/thx.2009.133280 20729231
Chalmers JD, Singanayagam A, Akram AR, Mandal P, Short PM, Choudhury G, et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax. 2010;65(10):878–83.20729231 10.1136/thx.2009.133280
10. Kaal AG Op de Hoek L Hochheimer DT Brouwers C Wiersinga WJ Snijders D Outcomes of community-acquired pneumonia using the Pneumonia Severity Index versus the CURB-65 in routine practice of emergency departments ERJ Open Res 2023 9 3 00051 2023 10.1183/23120541.00051-2023 37143846
Kaal AG, Op de Hoek L, Hochheimer DT, Brouwers C, Wiersinga WJ, Snijders D, et al. Outcomes of community-acquired pneumonia using the Pneumonia Severity Index versus the CURB-65 in routine practice of emergency departments. ERJ Open Res. 2023;9(3):00051–2023.37143846 10.1183/23120541.00051-2023
11. Alirio B-G Carolina A Alexandra ADBDSE Eduardo T-Q Gómez C Comparison of the performance of the CURB-65, A-DROP, and NEWS scores for the prediction of clinical outcomes in Pneumonia Infect Dis Clin Pract 2023 31 3 e1240
Alirio B-G, Carolina A, Alexandra ADBDSE, Eduardo T-Q, Gómez C, et al. Comparison of the performance of the CURB-65, A-DROP, and NEWS scores for the prediction of clinical outcomes in Pneumonia. Infect Dis Clin Pract. 2023;31(3):e1240.
12. Carmo TA Ferreira IB Menezes RC Telles GP Otero ML Arriaga MB Derivation and validation of a Novel Severity Scoring System for Pneumonia at Intensive Care Unit Admission Clin Infect Dis 2021 72 6 942 9 10.1093/cid/ciaa183 32146482
Carmo TA, Ferreira IB, Menezes RC, Telles GP, Otero ML, Arriaga MB, et al. Derivation and validation of a Novel Severity Scoring System for Pneumonia at Intensive Care Unit Admission. Clin Infect Dis. 2021;72(6):942–9.32146482 10.1093/cid/ciaa183
13. Limapichat T Supavajana S Comparison between the Severity Scoring systems A-DROP and CURB-65 for Predicting Safe Discharge from the Emergency Department in patients with community-acquired pneumonia Emerg Med Int 2022 2022 6391141 10.1155/2022/6391141 35480967
Limapichat T, Supavajana S. Comparison between the Severity Scoring systems A-DROP and CURB-65 for Predicting Safe Discharge from the Emergency Department in patients with community-acquired pneumonia. Emerg Med Int. 2022;2022:6391141.35480967 10.1155/2022/6391141
14. Martin-Loeches I Torres A Nagavci B Aliberti S Antonelli M Bassetti M ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia Intensive Care Med 2023 49 6 615 32 10.1007/s00134-023-07033-8 37012484
Martin-Loeches I, Torres A, Nagavci B, Aliberti S, Antonelli M, Bassetti M, et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med. 2023;49(6):615–32.37012484 10.1007/s00134-023-07033-8
15. Barberán J Restrepo R Cardinal-Fernández P Community-acquired pneumonia: similarities and differences between European and American guidelines - a narrative review Rev Esp Quimioter 2021 34 2 72 80 10.37201/req/114.2020 33291864
Barberán J, Restrepo R, Cardinal-Fernández P. Community-acquired pneumonia: similarities and differences between European and American guidelines - a narrative review. Rev Esp Quimioter. 2021;34(2):72–80.33291864 10.37201/req/114.2020
16. Lim WS van der Eerden MM Laing R Boersma WG Karalus N Town GI Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study Thorax 2003 58 5 377 82 10.1136/thorax.58.5.377 12728155
Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377–82.12728155 10.1136/thorax.58.5.377
17. España PP Capelastegui A Gorordo I Esteban C Oribe M Ortega M Bilbao A Development and validation of a clinical prediction rule for severe community-acquired pneumonia Am J Respir Crit Care Med 2006 174 11 1249 56 10.1164/rccm.200602-177OC 16973986
España PP, Capelastegui A, Gorordo I, Esteban C, Oribe M, Ortega M, Bilbao A, et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med. 2006;174(11):1249–56.16973986 10.1164/rccm.200602-177OC
18. Harris PA Taylor R Thielke R Payne J Gonzalez N Conde JG Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support J Biomed Inf 2009 42 2 377 81 10.1016/j.jbi.2008.08.010
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377–81.10.1016/j.jbi.2008.08.010
19. Harris PA Taylor R Minor BL Elliott V Fernandez M O’Neal L The REDCap consortium: building an international community of software platform partners J Biomed Inf 2019 95 103208 10.1016/j.jbi.2019.103208
Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inf. 2019;95:103208.10.1016/j.jbi.2019.103208
20. Hosmer DW Lemeshow S Sturdivant RX Hosmer DW Lemeshow S Sturdivant RX Special topics Applied Logistic Regression 2013 3 New York. NY John Wiley & Sons. Inc 401 8
Hosmer DW, Lemeshow S, Sturdivant RX. Special topics. In: Hosmer DW, Lemeshow S, Sturdivant RX, editors. Applied Logistic Regression. 3rd ed. New York. NY: John Wiley & Sons. Inc; 2013. pp. 401–8.
21. Nahm FS Receiver operating characteristic curve: overview and practical use for clinicians Korean J Anesthesiol 2022 75 1 25 36 10.4097/kja.21209 35124947
Nahm FS. Receiver operating characteristic curve: overview and practical use for clinicians. Korean J Anesthesiol. 2022;75(1):25–36.35124947 10.4097/kja.21209
22. Zaki HA Hamdi Alkahlout B Shaban E Mohamed EH Basharat K Elsayed WAE The battle of the Pneumonia predictors: a Comprehensive Meta-Analysis comparing the Pneumonia Severity Index (PSI) and the CURB-65 score in Predicting Mortality and the need for ICU support Cureus 2023 15 7 e42672 37649936
Zaki HA, Hamdi Alkahlout B, Shaban E, Mohamed EH, Basharat K, Elsayed WAE, et al. The battle of the Pneumonia predictors: a Comprehensive Meta-Analysis comparing the Pneumonia Severity Index (PSI) and the CURB-65 score in Predicting Mortality and the need for ICU support. Cureus. 2023;15(7):e42672.37649936
23. Marti C Garin N Grosgurin O Poncet A Combescure C Carballo S Perrier A Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis Crit Care 2012 16 4 R141 10.1186/cc11447 22839689
Marti C, Garin N, Grosgurin O, Poncet A, Combescure C, Carballo S, Perrier A. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care. 2012;16(4):R141.22839689 10.1186/cc11447
24. Saldías Peñafiel Fernando Uribe Monasterio Javier. Gassmann Poniachik Javiera. Canelo López Alejandro. Díaz Patiño Orlando. Evaluación De Los índices predictores de eventos adversos en El adulto inmunocompetente hospitalizado por neumonía adquirida en la comunidad Rev méd Chile 2017 145 6 694 702 10.4067/s0034-98872017000600694 29171616
Saldías Peñafiel Fernando. Uribe Monasterio Javier. Gassmann Poniachik Javiera. Canelo López Alejandro. Díaz Patiño Orlando. Evaluación De Los índices predictores de eventos adversos en El adulto inmunocompetente hospitalizado por neumonía adquirida en la comunidad. Rev méd Chile. 2017;145(6):694–702.29171616 10.4067/s0034-98872017000600694
25. Satici C Demirkol MA Sargin Altunok E Gursoy B Alkan M Kamat S Performance of pneumonia severity index and CURB-65 in predicting 30-day mortality in patients with COVID-19 Int J Infect Dis 2020 98 84 9 10.1016/j.ijid.2020.06.038 32553714
Satici C, Demirkol MA, Sargin Altunok E, Gursoy B, Alkan M, Kamat S, et al. Performance of pneumonia severity index and CURB-65 in predicting 30-day mortality in patients with COVID-19. Int J Infect Dis. 2020;98:84–9.32553714 10.1016/j.ijid.2020.06.038
26. McElvaney OJ McEvoy NL McElvaney OF Carroll TP Murphy MP Dunlea DM Characterization of the inflammatory response to severe COVID-19 illness Am J Respir Crit Care Med 2020 202 6 812 21 10.1164/rccm.202005-1583OC 32584597
McElvaney OJ, McEvoy NL, McElvaney OF, Carroll TP, Murphy MP, Dunlea DM, et al. Characterization of the inflammatory response to severe COVID-19 illness. Am J Respir Crit Care Med. 2020;202(6):812–21.32584597 10.1164/rccm.202005-1583OC
27. Hespanhol V Bárbara C Pneumonia mortality Comorbidities Matter? Pulmonol 2020 26 3 123 9
Hespanhol V, Bárbara C. Pneumonia mortality. Comorbidities Matter? Pulmonol. 2020;26(3):123–9.
28. Zhang ZX Yong Y Tan WC Shen L Ng HS Fong KY Prognostic factors for mortality due to pneumonia among adults from different age groups in Singapore and mortality predictions based on PSI and CURB-65 Singap Med J 2018 59 4 190 8 10.11622/smedj.2017079
Zhang ZX, Yong Y, Tan WC, Shen L, Ng HS, Fong KY. Prognostic factors for mortality due to pneumonia among adults from different age groups in Singapore and mortality predictions based on PSI and CURB-65. Singap Med J. 2018;59(4):190–8.10.11622/smedj.2017079
29. Reyes LF Bastidas Goyes A Tuta Quintero EA Pedreros KD Mantilla YF Herrera M Validity of the ROX index in predicting invasive mechanical ventilation requirement in pneumonia BMJ Open Respir Res 2022 9 1 e001320 10.1136/bmjresp-2022-001320 36104104
Reyes LF, Bastidas Goyes A, Tuta Quintero EA, Pedreros KD, Mantilla YF, Herrera M, et al. Validity of the ROX index in predicting invasive mechanical ventilation requirement in pneumonia. BMJ Open Respir Res. 2022;9(1):e001320.36104104 10.1136/bmjresp-2022-001320
30. Ferrer M Travierso C Cilloniz C Gabarrus A Ranzani OT Polverino E Severe community-acquired pneumonia: characteristics and prognostic factors in ventilated and non-ventilated patients PLoS ONE 2018 13 1 e0191721 10.1371/journal.pone.0191721 29370285
Ferrer M, Travierso C, Cilloniz C, Gabarrus A, Ranzani OT, Polverino E, et al. Severe community-acquired pneumonia: characteristics and prognostic factors in ventilated and non-ventilated patients. PLoS ONE. 2018;13(1):e0191721.29370285 10.1371/journal.pone.0191721
31. Mermiri M Mavrovounis G Laou E Papagiannakis N Pantazopoulos I Chalkias A Association of vasopressors with mortality in critically ill patients with COVID-19: a systematic review and meta-analysis APS 2023 1 2 10 10.1007/s44254-023-00013-7
Mermiri M, Mavrovounis G, Laou E, Papagiannakis N, Pantazopoulos I, Chalkias A. Association of vasopressors with mortality in critically ill patients with COVID-19: a systematic review and meta-analysis. APS. 2023;1(2):10.10.1007/s44254-023-00013-7
32. Saleem N Kulkarni A Snow TAC Ambler G Singer M Arulkumaran N Effect of corticosteroids on Mortality and Clinical Cure in Community-Acquired Pneumonia: a systematic review. Meta-analysis. And Meta-regression of Randomized Control trials Chest 2023 163 3 484 97 10.1016/j.chest.2022.08.2229 36087797
Saleem N, Kulkarni A, Snow TAC, Ambler G, Singer M, Arulkumaran N. Effect of corticosteroids on Mortality and Clinical Cure in Community-Acquired Pneumonia: a systematic review. Meta-analysis. And Meta-regression of Randomized Control trials. Chest. 2023;163(3):484–97.36087797 10.1016/j.chest.2022.08.2229
33. Shindo Y Ito R Kobayashi D Ando M Ichikawa M Goto Y Fukui Y Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: an observational cohort study Lancet Infect Dis 2015 15 9 1055 65 10.1016/S1473-3099(15)00151-6 26145194
Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Goto Y, Fukui Y, et al. Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: an observational cohort study. Lancet Infect Dis. 2015;15(9):1055–65.26145194 10.1016/S1473-3099(15)00151-6
34. Alfano G Fontana F Mori G Giaroni F Ferrari A Giovanella S Modena Covid-19 Working Group (MoCo19). Acid base disorders in patients with COVID-19 Int Urol Nephrol 2022 54 2 405 10 10.1007/s11255-021-02855-1 34115260
Alfano G, Fontana F, Mori G, Giaroni F, Ferrari A, Giovanella S, et al. Modena Covid-19 Working Group (MoCo19). Acid base disorders in patients with COVID-19. Int Urol Nephrol. 2022;54(2):405–10.34115260 10.1007/s11255-021-02855-1
35. Fernández-Sabé N, Carratalà J, Rosón B, Dorca J, Verdaguer R, Manresa F. el al Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. Medicine (Baltimore). 2003;82(3):159 – 69.
36. Al-Azzam N Khassawneh B Al-Azzam S Karasneh RA Aldeyab MA Acid-base imbalance as a risk factor for mortality among COVID-19 hospitalized patients Biosci Rep 2023 43 3 BSR20222362 10.1042/BSR20222362 36876487
Al-Azzam N, Khassawneh B, Al-Azzam S, Karasneh RA, Aldeyab MA. Acid-base imbalance as a risk factor for mortality among COVID-19 hospitalized patients. Biosci Rep. 2023;43(3):BSR20222362.36876487 10.1042/BSR20222362
37. Murugan R Karajala-Subramanyam V Lee M Yende S Kong L Carter M Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival Kidney Int 2010 77 6 527 35 10.1038/ki.2009.502 20032961
Murugan R, Karajala-Subramanyam V, Lee M, Yende S, Kong L, Carter M, et al. Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival. Kidney Int. 2010;77(6):527–35.20032961 10.1038/ki.2009.502
